Optimizing T-cell Therapies in Multiple Myeloma: Key Insights and Strategies
The management of multiple myeloma (MM) is evolving with the advent of T-cell redirecting therapies (TCRT), such as chimeric antigen receptor T (CAR T)-cell therapies and bispecific T-cell...
MS, MMSc, PA-C
Associate Chief of Education, Winship Cancer Institute of Emory University
Patient Management Guidelines
National Comprehensive Cancer Network Clinical Practice Guidelines
The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
Integrative Approaches in Multiple Myeloma: Managing Symptoms and Improving Quality of Life
Multiple myeloma (MM) has seen significant treatment advancements, including immune modulators, proteasome inhibitors, and chimeric antigen receptor T cell therapies, resulting in a tripling of median overall survival....
Balancing Efficacy and Safety: Managing Adverse Events With IMiDs in Multiple Myeloma
Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide are integral to multiple myeloma (MM) treatment, improving survival and quality of life....
High-Fiber Plant-Based Diet Delays Progression From MGUS/SMM to Multiple Myeloma in Pilot Study
Researchers of this pilot study assessed the impact of a high-fiber plant-based dietary (HFPBD) intervention on 20 patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM)....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Advances in Diagnosing and Treating High-Risk Multiple Myeloma
High-risk multiple myeloma (MM) is a challenging condition to diagnose and treat, requiring effective tools to identify patients and deliver targeted therapies....
CHIP Tied to Higher CVD Risk in Patients With Multiple Myeloma Undergoing HCT
Researchers of a study investigating the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease (CVD) among patients with multiple myeloma (MM) undergoing hematopoietic stem cell transplant (HCT)...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
